[SCHEDULE 13G] Oruka Therapeutics, Inc. SEC Filing
Oruka Therapeutics, Inc. received a Schedule 13G reporting that a group of Viking-related entities and three named individuals may be deemed to beneficially own 2,666,690 shares of the company’s common stock, representing 5.5% of the outstanding class based on 48,384,150 shares outstanding following a private placement. The filing breaks ownership down: Viking Global Opportunities (VGOP) directly owns 1,600,014 shares (3.3%) and Viking Global Opportunities Drawdown (VGOD) directly owns 1,066,676 shares (2.2%). All reporting persons report only shared voting and dispositive power and no sole voting or dispositive power. The filing lists Oruka’s principal executive office in Menlo Park, CA, and provides the reporting persons’ business address in Stamford, CT. Signatures are dated 09/24/2025.
Oruka Therapeutics, Inc. ha ricevuto una Schedule 13G che indica che un gruppo di entità legate a Viking e tre individui nominati potrebbero detenere in modo beneficiario 2.666.690 azioni delle azioni ordinarie della società, pari al 5,5% della classe in circolazione, basato su 48.384.150 azioni in circolazione dopo un private placement. La documentazione suddivide la proprietà: Viking Global Opportunities (VGOP) detiene direttamente 1.600.014 azioni (3,3%) e Viking Global Opportunities Drawdown (VGOD) detiene direttamente 1.066.676 azioni (2,2%). Tutti i soggetti riportanti dichiarano solo potere di voto e dispositivi condiviso e nessun potere di voto o dispositivi esclusivo. La documentazione indica l’ufficio esecutivo principale di Oruka a Menlo Park, CA, e fornisce l’indirizzo aziendale dei soggetti riportanti a Stamford, CT. Le firme sono datate 24/09/2025.
Oruka Therapeutics, Inc. recibió un Schedule 13G que indica que un grupo de entidades relacionadas con Viking y tres individuos mencionados pueden ser considerados beneficiarios de 2.666.690 acciones de las acciones ordinarias de la compañía, equivalente al 5,5% de la clase en circulación, basado en 48.384.150 acciones en circulación tras una colocación privada. La presentación desglosa la propiedad: Viking Global Opportunities (VGOP) posee directamente 1.600.014 acciones (3,3%) y Viking Global Opportunities Drawdown (VGOD) posee directamente 1.066.676 acciones (2,2%). Todos los reportantes informan solo poder de voto y dispositiva compartidos y no tienen poder de voto o dispositiva exclusivo. La presentación lista la oficina ejecutiva principal de Oruka en Menlo Park, CA, y proporciona las direcciones comerciales de los reportantes en Stamford, CT. Las firmas están fechadas el 24/09/2025.
Oruka Therapeutics, Inc.는 Viking 관련 그룹의 여러 법인과 세 명의 명시된 개인들이 회사의 보통주 2,666,690주를 실질적으로 소유할 수 있다고 보는 Schedule 13G를 수령했으며, 이는 발행 주식의 5.5%에 해당합니다. 이는 비공개 배정(private placement) 이후 발행 주식 48,384,150주를 기준으로 합니다. 제출서는 소유를 아래와 같이 분류합니다: Viking Global Opportunities (VGOP)가 직접 1,600,014주를 보유(3.3%)하고, Viking Global Opportunities Drawdown (VGOD)가 직접 1,066,676주를 보유(2.2%)합니다. 모든 보고자는 공동 의결권 및 처분권만 보고하며 단독 의결권이나 처분권은 없다고 명시합니다. 제출서는 Oruka의 본사(기업 사무소)가 Menlo Park, CA에 있음을, 보고자들의 사업 주소가 Stamford, CT임을 lists합니다. 서명일은 2025년 9월 24일입니다.
Oruka Therapeutics, Inc. a reçu un Schedule 13G indiquant qu’un groupe d’entités liées à Viking et trois personnes nommées pourraient être considérés comme bénéficiaires de 2 666 690 actions des actions ordinaires de la société, représentant 5,5% de la classe en circulation après une levée privée. Le dossier décompose la propriété: Viking Global Opportunities (VGOP) détient directement 1 600 014 actions (3,3%) et Viking Global Opportunities Drawdown (VGOD) détient directement 1 066 676 actions (2,2%). Toutes les personnes déclarantes indiquent uniquement un pouvoir de vote et de dispositif partagé et aucun pouvoir de vote ou dispositif exclusif. Le dossier indique le siège social principal d’Oruka à Menlo Park, CA, et fournit l’adresse professionnelle des personnes déclarantes à Stamford, CT. Les signatures datent du 24/09/2025.
Oruka Therapeutics, Inc. erhielt ein Schedule 13G, das besagt, dass eine Gruppe Viking-bezogener Einheiten und drei namentlich genannte Personen potenziell als wirtschaftlich berechtigt 2.666.690 Aktien der Stammaktien des Unternehmens halten könnten, was 5,5% der umlaufenden Klasse entspricht, basierend auf 48.384.150 Aktien im Umlauf nach einer privaten Platzierung. Die Einreichung führt die Eigentumsverhältnisse wie folgt auf: Viking Global Opportunities (VGOP) besitzt direkt 1.600.014 Aktien (3,3%) und Viking Global Opportunities Drawdown (VGOD) besitzt direkt 1.066.676 Aktien (2,2%). Alle meldenden Personen berichten nur gemeinsame Stimm- und Verfügungsgewalt und keine alleinige Stimm- oder Verfügungsgewalt. Die Einreichung nennt das principal executive office von Oruka in Menlo Park, CA, und gibt die Geschäftsadressen der meldenden Personen in Stamford, CT, an. Die Unterschriften datieren vom 24.09.2025.
Oruka Therapeutics, Inc. استلمت نموذج Schedule 13G يشير إلى أن مجموعة من الكيانات المرتبطة بـ Viking وثلاثة أفراد مُذكرين قد يُنظر إليهم كمالكين فعليين 2,666,690 سهمًا من أسهم الشركة العادية، ما يمثل 5.5% من الفئة القائمة على أساس 48,384,150 سهمًا قائمًا بعد عرض خاص. تقسم الإيداع الملكية كما يلي: Viking Global Opportunities (VGOP) تمتلك مباشرة 1,600,014 سهمًا (3.3%) وViking Global Opportunities Drawdown (VGOD) تمتلك مباشرة 1,066,676 سهمًا (2.2%). جميع الأطراف المبلغة يبلغون عن سلطة تصويت مشتركة وتصرّف مشتركة فقط ولا سلطة تصويت أو تصرف حصرية. يذكر الإيداع المقر الإداري التنفيذي الرئيسي لـ Oruka في Menlo Park, CA، ويقدّم عناوين الأعمال للأطراف المبلّغة في Stamford, CT. التواقيع مؤرخة في 24/09/2025.
Oruka Therapeutics, Inc. 收到了一份 Schedule 13G,表明与 Viking 相关的一组实体及三位被命名个人可能被视为对公司普通股的受益所有人,合计拥有2,666,690 股,占已发行股本的5.5%(在私募发行后,流通股为48,384,150股)。该备案将所有权分解为:Viking Global Opportunities (VGOP)直接拥有1,600,014 股(3.3%),Viking Global Opportunities Drawdown (VGOD)直接拥有1,066,676 股(2.2%)。所有申报人仅报告共用投票权和处置权,未报告单独投票权或处置权。备案列出Oruka在门洛帕克,CA的主要办公地点,并提供申报方的商业地址在斯坦福,CT。签名日期为2025-09-24。
- Disclosure compliance: The reporting group filed a Schedule 13G clearly disclosing beneficial ownership above the 5% threshold.
- Detailed attribution: The filing provides a clear breakdown of ownership by entity (VGOP 1,600,014; VGOD 1,066,676) and percent of class.
- None.
Insights
TL;DR: Viking-affiliated group holds a disclosed 5.5% stake, split between two investment vehicles (3.3% and 2.2%).
The Schedule 13G indicates passive reporting under Section 13(g) structure with shared voting and dispositive power across affiliated entities and three executive committee members. The stake equals 5.5% of shares outstanding after a recent private placement, which crosses the common 5% reporting threshold and therefore requires disclosure. The structure shows layered ownership through funds and GPs, but the filing reports no sole control and includes the required joint filing agreement. This is a disclosure of ownership rather than an assertion of control or a change in corporate governance.
TL;DR: Ownership is material for disclosure but presented as passive with shared authority, not an active control claim.
The filing clarifies beneficial ownership attribution under Rule 13d-3 through fund and GP relationships and notes that executive committee members may be deemed to beneficially own the shares held by the funds. All reported powers are shared; no individual or entity claims sole voting or dispositive authority. The document includes authorized signatures and a joint filing agreement, satisfying procedural requirements for a grouped 13G filing.
Oruka Therapeutics, Inc. ha ricevuto una Schedule 13G che indica che un gruppo di entità legate a Viking e tre individui nominati potrebbero detenere in modo beneficiario 2.666.690 azioni delle azioni ordinarie della società, pari al 5,5% della classe in circolazione, basato su 48.384.150 azioni in circolazione dopo un private placement. La documentazione suddivide la proprietà: Viking Global Opportunities (VGOP) detiene direttamente 1.600.014 azioni (3,3%) e Viking Global Opportunities Drawdown (VGOD) detiene direttamente 1.066.676 azioni (2,2%). Tutti i soggetti riportanti dichiarano solo potere di voto e dispositivi condiviso e nessun potere di voto o dispositivi esclusivo. La documentazione indica l’ufficio esecutivo principale di Oruka a Menlo Park, CA, e fornisce l’indirizzo aziendale dei soggetti riportanti a Stamford, CT. Le firme sono datate 24/09/2025.
Oruka Therapeutics, Inc. recibió un Schedule 13G que indica que un grupo de entidades relacionadas con Viking y tres individuos mencionados pueden ser considerados beneficiarios de 2.666.690 acciones de las acciones ordinarias de la compañía, equivalente al 5,5% de la clase en circulación, basado en 48.384.150 acciones en circulación tras una colocación privada. La presentación desglosa la propiedad: Viking Global Opportunities (VGOP) posee directamente 1.600.014 acciones (3,3%) y Viking Global Opportunities Drawdown (VGOD) posee directamente 1.066.676 acciones (2,2%). Todos los reportantes informan solo poder de voto y dispositiva compartidos y no tienen poder de voto o dispositiva exclusivo. La presentación lista la oficina ejecutiva principal de Oruka en Menlo Park, CA, y proporciona las direcciones comerciales de los reportantes en Stamford, CT. Las firmas están fechadas el 24/09/2025.
Oruka Therapeutics, Inc.는 Viking 관련 그룹의 여러 법인과 세 명의 명시된 개인들이 회사의 보통주 2,666,690주를 실질적으로 소유할 수 있다고 보는 Schedule 13G를 수령했으며, 이는 발행 주식의 5.5%에 해당합니다. 이는 비공개 배정(private placement) 이후 발행 주식 48,384,150주를 기준으로 합니다. 제출서는 소유를 아래와 같이 분류합니다: Viking Global Opportunities (VGOP)가 직접 1,600,014주를 보유(3.3%)하고, Viking Global Opportunities Drawdown (VGOD)가 직접 1,066,676주를 보유(2.2%)합니다. 모든 보고자는 공동 의결권 및 처분권만 보고하며 단독 의결권이나 처분권은 없다고 명시합니다. 제출서는 Oruka의 본사(기업 사무소)가 Menlo Park, CA에 있음을, 보고자들의 사업 주소가 Stamford, CT임을 lists합니다. 서명일은 2025년 9월 24일입니다.
Oruka Therapeutics, Inc. a reçu un Schedule 13G indiquant qu’un groupe d’entités liées à Viking et trois personnes nommées pourraient être considérés comme bénéficiaires de 2 666 690 actions des actions ordinaires de la société, représentant 5,5% de la classe en circulation après une levée privée. Le dossier décompose la propriété: Viking Global Opportunities (VGOP) détient directement 1 600 014 actions (3,3%) et Viking Global Opportunities Drawdown (VGOD) détient directement 1 066 676 actions (2,2%). Toutes les personnes déclarantes indiquent uniquement un pouvoir de vote et de dispositif partagé et aucun pouvoir de vote ou dispositif exclusif. Le dossier indique le siège social principal d’Oruka à Menlo Park, CA, et fournit l’adresse professionnelle des personnes déclarantes à Stamford, CT. Les signatures datent du 24/09/2025.
Oruka Therapeutics, Inc. erhielt ein Schedule 13G, das besagt, dass eine Gruppe Viking-bezogener Einheiten und drei namentlich genannte Personen potenziell als wirtschaftlich berechtigt 2.666.690 Aktien der Stammaktien des Unternehmens halten könnten, was 5,5% der umlaufenden Klasse entspricht, basierend auf 48.384.150 Aktien im Umlauf nach einer privaten Platzierung. Die Einreichung führt die Eigentumsverhältnisse wie folgt auf: Viking Global Opportunities (VGOP) besitzt direkt 1.600.014 Aktien (3,3%) und Viking Global Opportunities Drawdown (VGOD) besitzt direkt 1.066.676 Aktien (2,2%). Alle meldenden Personen berichten nur gemeinsame Stimm- und Verfügungsgewalt und keine alleinige Stimm- oder Verfügungsgewalt. Die Einreichung nennt das principal executive office von Oruka in Menlo Park, CA, und gibt die Geschäftsadressen der meldenden Personen in Stamford, CT, an. Die Unterschriften datieren vom 24.09.2025.